DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Spasmodic Dysphonia (SD) is a neurologic condition causing inappropriate contraction of the
laryngeal musculature, leading to abnormal voicing. The three types (adductor, abductor, and
mixed) affect varying muscle groups which produce characteristic voice patterns. The vast
majority of patients with SD have adductor type, which impacts the lateral cricoarytenoid and
thyroarytenoid muscle complex. While many treatment modalities have been investigated, the
most effective treatment is botulinum toxin injection to these muscle groups, performed
transcervically with or without electromyography (EMG) guidance. Patients undergoing this
treatment typically require re-injection every 3 months. Due to its specialized nature, the
laryngeal injections are not performed routinely outside of academic medical centers; thus,
patients may come from a distance to receive this treatment. Both due to the significant
impact on voice quality when the injections wear off and the sometimes challenging access to
treatment, a longer-acting agent is desired.
Injectible daxibotuliumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) has been shown in
large clinical trials to provide safe, effective treatment for glabellar lines and cervical
dystonia and may offer a longer-lasting result when compared with onabotulinumtoxinA.
Thus, a study examining the effect of DAXI for patients with adductor spasmodic dysphonia is
proposed. This study aims to assess the efficacy of DAXI for transcervical laryngeal
injection in patients with adductor spasmodic dysphonia.